Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-events, financials, filing
Related Tickers: ALDX
TL;DR
Aldeyra Therapeutics filed an 8-K on 10/28/25. Standard update.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on October 28, 2025, reporting other events and financial statements. The company, previously known as Aldexa Therapeutics, Inc. and Neuron Systems Inc., is incorporated in Delaware and headquartered in Lexington, MA.
Why It Matters
This filing provides an update on Aldeyra Therapeutics' corporate events and financial status, which is crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate events and financial statements, not indicating any immediate significant risks.
Key Numbers
- 001-36332 — SEC File Number (Identifies the company's filing with the SEC)
- 20251028 — Report Date (Date of the earliest event reported in the 8-K)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- Aldexa Therapeutics, Inc. (company) — Former company name
- Neuron Systems Inc (company) — Former company name
- Lexington, MA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Aldeyra Therapeutics?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 28, 2025.
What were Aldeyra Therapeutics' previous names?
Aldeyra Therapeutics, Inc. was formerly known as Aldexa Therapeutics, Inc. and Neuron Systems Inc.
Where are Aldeyra Therapeutics' principal executive offices located?
The principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What is the SEC file number for Aldeyra Therapeutics?
The SEC file number for Aldeyra Therapeutics is 001-36332.
What is the fiscal year end for Aldeyra Therapeutics?
The fiscal year end for Aldeyra Therapeutics is December 31 (1231).
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-10-28 07:00:28
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- aldx-20251028.htm (8-K) — 59KB
- aldx-ex99_1.htm (EX-99.1) — 29KB
- img112526854_0.jpg (GRAPHIC) — 196KB
- 0001193125-25-252200.txt ( ) — 475KB
- aldx-20251028.xsd (EX-101.SCH) — 30KB
- aldx-20251028_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On October 28, 2025, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") to announce positive results from a Phase 2 clinical trial in alcohol-associated hepatitis, the prioritization of the Company's RASP modulator product candidates, an updated pipeline, and the extension of the Company's projected operational cash runway into the second half of 2027. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated October 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady M.D., Ph.D. Title: Chief Executive Officer Dated October 28, 2025